Updates on the latest news, research and collaborations emerging from IBRI.
News & Publications
Keep up with our progress
Newsroom
Annual Reports
Publications & Presentations
02/01/2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Read more
01/11/2024
RIPK3 promotes islet amyloid-induced ß-cell loss and glucose intolerance in a humanized mouse model of type 2 diabetes
Read more
01/03/2024
Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric P13Ka inhibitor that decouples antitumor activity from hyperinsulinemia
Read more
10/05/2023
Which small molecule? Selecting chemical probes for use in cancer research and target validation
Read more
07/05/2023
Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes
Read more
11/22/2022
Therapeutic strategies targeting pancreatic islet beta-cell proliferation, regeneration and replacement
Read more
Keep me updated
Sign up for our newsletter to stay updated on IBRI’s progress.
"*" indicates required fields